Product Data Sheet

Triclabendazole-¹³C,d₃

Cat. No.: HY-B0621S1

Molecular Formula: $C_{13}^{13}CH_6D_3Cl_3N_2OS$

Molecular Weight: 363.67

Target: Microtubule/Tubulin; Parasite; Isotope-Labeled Compounds

Pathway: Cell Cycle/DNA Damage; Cytoskeleton; Anti-infection; Others

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	$\label{thm:condition} {\sf Triclabendazole}. \\ {\sf 13C,d_3} \ {\sf is the} \ {\sf 13C-and deuterium labeled Triclabendazole} [1].$
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[52] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

[2]. Fairweather, I., Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol, 2005. 79(3): p. 227-34.

[3]. Moll, L., et al., Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The netherlands. Vet Parasitol, 2000. 91(1-2): p. 153-8.

[4]. Robinson, M.W., et al., Triclabendazole-resistant Fasciola hepatica: beta-tubulin and response to in vitro treatment with triclabendazole. Parasitology, 2002. 124(Pt 3): p. 325-38.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA